Durvalumab (MEDI4736) is a human IgG1 antibody with high affinity of PD‐L1, which was approved by the U.S. FDA as adjuvant treatment of unresectable advanced NSCLC, whose disease has not progressed following concurrent platinum‐based chemotherapy and radiation therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.